Royal Bank of Canada’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.31M | Buy |
13,645
+1,571
| +13% | +$271K | ﹤0.01% | 2982 |
|
|
2025
Q4 | $2.21M | Buy |
12,074
+1,019
| +9% | +$142K | ﹤0.01% | 3066 |
|
|
2025
Q3 | $1.34M | Buy |
11,055
+3,414
| +45% | +$385K | ﹤0.01% | 3739 |
|
|
2025
Q2 | $797K | Buy |
7,641
+840
| +12% | +$88.9K | ﹤0.01% | 4092 |
|
|
2025
Q1 | $794K | Sell |
6,801
-14,114
| -67% | -$1.61M | ﹤0.01% | 3639 |
|
|
2024
Q4 | $1.77M | Buy |
20,915
+5,267
| +34% | +$484K | ﹤0.01% | 3104 |
|
|
2024
Q3 | $1.41M | Sell |
15,648
-496
| -3% | -$43.3K | ﹤0.01% | 3264 |
|
|
2024
Q2 | $1.3M | Buy |
16,144
+131
| +0.8% | +$9.7K | ﹤0.01% | 3238 |
|
|
2024
Q1 | $1.28M | Sell |
16,013
-10,224
| -39% | -$858K | ﹤0.01% | 3257 |
|
|
2023
Q4 | $2.09M | Buy |
26,237
+6,384
| +32% | +$427K | ﹤0.01% | 3049 |
|
|
2023
Q3 | $1.39M | Buy |
19,853
+12,520
| +171% | +$936K | ﹤0.01% | 3162 |
|
|
2023
Q2 | $527K | Buy |
7,333
+1,909
| +35% | +$141K | ﹤0.01% | 3911 |
|
|
2023
Q1 | $335K | Sell |
5,424
-2,949
| -35% | -$194K | ﹤0.01% | 4197 |
|
|
2022
Q4 | $646K | Buy |
8,373
+3,877
| +86% | +$232K | ﹤0.01% | 3869 |
|
|
2022
Q3 | $201K | Buy |
4,496
+712
| +19% | +$35.6K | ﹤0.01% | 4768 |
|
|
2022
Q2 | $144K | Sell |
3,784
-2,078
| -35% | -$65.7K | ﹤0.01% | 5058 |
|
|
2022
Q1 | $242K | Sell |
5,862
-3,804
| -39% | -$118K | ﹤0.01% | 4916 |
|
|
2021
Q4 | $365K | Buy |
9,666
+2,920
| +43% | +$107K | ﹤0.01% | 4758 |
|
|
2021
Q3 | $223K | Buy |
6,746
+3,208
| +91% | +$125K | ﹤0.01% | 5069 |
|
|
2021
Q2 | $238K | Buy |
3,538
+708
| +25% | +$42.5K | ﹤0.01% | 4930 |
|
|
2021
Q1 | $160K | Buy |
2,830
+2,662
| +1,585% | +$187K | ﹤0.01% | 5113 |
|
|
2020
Q4 | $14K | Buy |
168
+136
| +425% | +$10.2K | ﹤0.01% | 6216 |
|
|
2020
Q3 | $2K | Sell |
32
-176
| -85% | -$13.7K | ﹤0.01% | 6295 |
|
|
2020
Q2 | $17K | Buy |
208
+102
| +96% | +$7.85K | ﹤0.01% | 5645 |
|
|
2020
Q1 | $6K | Buy |
+106
| New | +$8.64K | ﹤0.01% | 5967 |
|
|
2018
Q4 | – | Sell |
-39
| Closed | – | – | 6735 |
|
|
2018
Q3 | $0 | Buy |
+39
| New | +$116 | ﹤0.01% | 6709 |
|
|
2018
Q1 | – | Sell |
-19
| Closed | – | – | 6331 |
|
|
2017
Q4 | $0 | Buy |
19
+16
| +533% | +$81 | ﹤0.01% | 6531 |
|
|
2017
Q3 | $0 | Buy |
+3
| New | +$16 | ﹤0.01% | 6704 |
|
|
2017
Q2 | – | Sell |
-696
| Closed | -$3K | – | 6552 |
|
|
2017
Q1 | $3K | Sell |
696
-63
| -8% | -$301 | ﹤0.01% | 6335 |
|
|
2016
Q4 | $5K | Buy |
+759
| New | +$5.33K | ﹤0.01% | 6290 |
|
Other funds holding AXSM
VPM
VCM
DTC
Royal Bank of Canada's AXSM Position: Q1 2026 in Review
Royal Bank of Canada increased its Axsome Therapeutics (AXSM) stake by 13% in Q1 2026, buying an estimated $271K and bringing the position to 13,645 shares worth $2.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2982.
Royal Bank of Canada first reported a position in AXSM in Q4 2016 and has held it in 30 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.
- Royal Bank of Canada held 13,645 shares of Axsome Therapeutics worth $2.31M as of Q1 2026.
- Royal Bank of Canada bought 1,571 Axsome Therapeutics shares in Q1 2026, an estimated $271K.
- Axsome Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #2982 holding.
- Royal Bank of Canada first reported a position in Axsome Therapeutics in Q4 2016 and has held it in 30 quarters since.
- 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.